SCHEMBL366707

SCHEMBL366707

Cc1ccc(Oc2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)nc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 20/20 0.56
SCN5A Q14524 4/20 0.48
CYP2C9 P11712 2/20 0.46
SCN1A P35498 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2C19 P33261 1/20 0.46
ABCB11 O95342 1/20 0.46
SCN4A P35499 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
SCN10A Q9Y5Y9 1/20 0.46
SCN2B O60939 1/20 0.46
SCN1B Q07699 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1690238 0.88 SCN9A (0.61) SCN9ASCN5ACYP2C9SCN1AABCB11
SCHEMBL16174988 0.86 SCN9A (0.56) SCN9ASCN5A
SCHEMBL1690179 0.85 SCN9A (0.53) SCN9ASCN5ACYP2C9SCN1ACYP3A4
SCHEMBL365530 0.84 SCN9A (0.56) SCN9ASCN5ACYP2C9SCN1AABCB11
SCHEMBL365121 0.82 SCN9A (0.63) SCN9ASCN5ACYP2C9SCN1AABCB11
SCHEMBL16319360 0.82 SCN9A (0.62) SCN9ASCN5ACYP2C9SCN1AABCB11
SCHEMBL680082 0.82 SCN9A (0.72) SCN9ASCN5ASCN1ASCN2BSCN1B
SCHEMBL1690180 0.81 SCN9A (0.55) SCN9ASCN5ACYP2C9SCN1AABCB11
SCHEMBL16175229 0.81 SCN9A (0.55) SCN9ASCN5ACYP2C9SCN1AABCB11
SCHEMBL363461 0.80 SCN9A (0.60) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
US-8592629-B2 Sulfonamide derivatives as Nav 1.7 inhibitors PFIZER LIMITED (GB) 2013-11-26 US disclosed
EP-2593432-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010183-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN9A 25/4885SCN5A 4/4885CYP2C9 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.